Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.3300 (-3.88%) ($5.3300 - $5.3300) on Wed. Jan. 27, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.66% (three month average) | RSI | 48 | Latest Price | $5.3300(-3.88%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -1.6% a day on average for past five trading days. | Weekly Trend | ADAP declines -4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) IGOV(85%) IFRA(47%) PAVE(40%) XME(40%) BLOK(39%) | Factors Impacting ADAP price | ADAP will decline at least -2.33% in a week (0% probabilities). TLT(-23%) VXX(-19%) VCIT(-17%) UUP(-10%) TIP(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.33% (StdDev 4.66%) | Hourly BBV | -1.6 () | Intraday Trend | 0% | | | |
|
Resistance Level | $5.73 | 5 Day Moving Average | $5.52(-3.44%) | 10 Day Moving Average | $5.69(-6.33%) | 20 Day Moving Average | $5.73(-6.98%) | To recent high | -14.2% | To recent low | 6.1% | Market Cap | $824m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |